ALLO
Allogene Therapeutics, Inc. NASDAQ Listed Oct 11, 2018$2.27
Mkt Cap $553.6M
52w Low $0.86
39.2% of range
52w High $4.46
50d MA $2.42
200d MA $1.63
P/E (TTM)
-2.5x
EV/EBITDA
-1.7x
P/B
1.6x
Debt/Equity
0.3x
ROE
-65.2%
P/FCF
-2.0x
RSI (14)
—
ATR (14)
—
Beta
0.54
50d MA
$2.42
200d MA
$1.63
Avg Volume
9.6M
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
210 East Grand Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.25 | -0.17 | +32.0% | 2.47 | +3.6% | -2.8% | -1.2% | -8.1% | -13.0% | -10.1% | — |
| Nov 6, 2025 | AMC | -0.23 | -0.19 | +17.4% | 1.05 | +0.0% | +12.4% | +12.4% | +18.1% | +17.1% | +14.3% | — |
| Aug 13, 2025 | AMC | -0.28 | -0.23 | +17.9% | 1.04 | +1.0% | +2.9% | +5.8% | +4.8% | +1.0% | +1.9% | — |
| May 13, 2025 | AMC | -0.28 | -0.28 | +0.0% | 1.13 | -2.7% | -15.7% | -3.5% | -1.8% | -3.5% | +2.7% | — |
| Mar 13, 2025 | AMC | -0.34 | -0.28 | +17.6% | 1.89 | +7.4% | +2.6% | -2.1% | -10.6% | -10.6% | -13.8% | — |
| Nov 7, 2024 | AMC | -0.34 | -0.27 | +20.6% | 3.19 | +1.6% | -3.4% | -3.1% | -11.0% | -14.7% | -22.9% | — |
| Aug 7, 2024 | AMC | -0.35 | -0.32 | +8.6% | 2.47 | +5.3% | -4.5% | -6.1% | -4.5% | -4.9% | -8.9% | — |
| May 13, 2024 | AMC | -0.38 | -0.38 | +0.0% | 2.90 | +12.1% | +2.1% | +2.8% | +3.8% | -4.5% | -10.7% | — |
| Mar 14, 2024 | AMC | -0.47 | -0.43 | +8.5% | 4.50 | -1.1% | +3.6% | -6.7% | -2.4% | -1.6% | -2.7% | — |
| Nov 2, 2023 | AMC | -0.53 | -0.37 | +30.2% | 2.97 | +5.4% | +17.8% | +6.4% | +10.4% | -3.7% | -15.3% | — |
| Aug 2, 2023 | AMC | -0.59 | -0.53 | +10.2% | 4.69 | +3.0% | +9.6% | -2.1% | -9.4% | -4.9% | -7.5% | — |
| May 3, 2023 | AMC | -0.63 | -0.68 | -7.9% | 5.72 | -0.3% | +12.8% | +15.4% | +10.5% | +8.9% | +11.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.23 | +2.8% | +9.2% | +10.1% | +11.5% | +6.9% | +10.1% |
| Apr 16 | JP Morgan | Upgrade | Underweight → Neutral | — | $2.17 | $2.23 | +2.8% | +9.2% | +10.1% | +11.5% | +6.9% | +10.1% |
| Apr 15 | Jefferies | Maintains | Buy → Buy | — | $2.28 | $1.90 | -16.7% | -4.8% | +3.9% | +4.8% | +6.1% | +1.8% |
| Apr 14 | Argus | Maintains | Market Perform → Market Perform | — | $3.06 | $3.03 | -1.0% | -25.5% | -29.1% | -22.5% | -21.9% | -20.9% |
| Apr 14 | Baird | Maintains | Outperform → Outperform | — | $3.06 | $3.03 | -1.0% | -25.5% | -29.1% | -22.5% | -21.9% | -20.9% |
| Apr 14 | Bernstein | Maintains | Market Perform → Market Perform | — | $3.06 | $3.03 | -1.0% | -25.5% | -29.1% | -22.5% | -21.9% | -20.9% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.06 | $3.03 | -1.0% | -25.5% | -29.1% | -22.5% | -21.9% | -20.9% |
| Apr 14 | Citizens | Maintains | Market Outperform → Market Outperform | — | $3.06 | $3.03 | -1.0% | -25.5% | -29.1% | -22.5% | -21.9% | -20.9% |
| Mar 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.47 | $2.56 | +3.6% | -2.8% | -1.2% | -8.1% | -13.0% | -10.1% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.47 | $2.56 | +3.6% | -2.8% | -1.2% | -8.1% | -13.0% | -10.1% |
| Jan 9 | Citizens | Upgrade | Market Perform → Market Outperform | — | $1.49 | $1.66 | +11.4% | +14.8% | +12.1% | +10.1% | +14.1% | +8.1% |
| Oct 10 | JP Morgan | Downgrade | Neutral → Underweight | — | $1.51 | $1.44 | -4.6% | -18.5% | -15.9% | -18.5% | -15.9% | -15.9% |
| Aug 4 | JMP Securities | Maintains | Market Perform → Market Perform | — | $1.08 | $1.11 | +2.8% | +1.9% | +3.7% | -1.9% | -2.8% | -3.7% |
| Aug 4 | JP Morgan | Downgrade | Overweight → Neutral | — | $1.08 | $1.11 | +2.8% | +1.9% | +3.7% | -1.9% | -2.8% | -3.7% |
| Aug 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.23 | $1.23 | +0.0% | -12.2% | -10.6% | -8.9% | -13.8% | -14.6% |
| May 15 | Citigroup | Maintains | Buy → Buy | — | $0.95 | $0.95 | -0.3% | +14.4% | +16.5% | +14.4% | +21.7% | +16.5% |
| May 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.13 | $1.10 | -2.7% | -15.7% | -3.5% | -1.8% | -3.5% | +2.7% |
| May 14 | Baird | Maintains | Outperform → Outperform | — | $1.13 | $1.10 | -2.7% | -15.7% | -3.5% | -1.8% | -3.5% | +2.7% |
| May 14 | Truist | Maintains | Buy → Buy | — | $1.13 | $1.10 | -2.7% | -15.7% | -3.5% | -1.8% | -3.5% | +2.7% |
| May 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.13 | $1.10 | -2.7% | -15.7% | -3.5% | -1.8% | -3.5% | +2.7% |
| May 14 | RBC Capital | Maintains | Outperform → Outperform | — | $1.13 | $1.10 | -2.7% | -15.7% | -3.5% | -1.8% | -3.5% | +2.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.69 | $1.69 | +0.0% | +0.0% | -3.6% | -4.1% | -0.6% | -5.3% |
| Mar 14 | RBC Capital | Maintains | Outperform → Outperform | — | $1.89 | $2.03 | +7.4% | +2.6% | -2.1% | -10.6% | -10.6% | -13.8% |
| Mar 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.89 | $2.03 | +7.4% | +2.6% | -2.1% | -10.6% | -10.6% | -13.8% |
| Mar 14 | Citizens Capital Markets | Upgrade | Market Perform → Market Outperform | — | $1.89 | $2.03 | +7.4% | +2.6% | -2.1% | -10.6% | -10.6% | -13.8% |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.72 | $2.72 | +0.0% | -9.6% | -16.5% | -21.0% | -22.1% | -24.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.19 | $3.24 | +1.6% | -3.4% | -3.1% | -11.0% | -14.7% | -22.9% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $2.74 | -2.1% | -5.7% | -8.6% | -2.9% | +7.1% | +6.8% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $2.30 | +2.2% | +2.2% | +1.8% | +17.8% | +17.3% | +21.8% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $2.36 | $2.40 | +1.7% | -1.7% | +0.0% | -0.4% | -4.7% | -2.5% |
| Aug 9 | Truist | Maintains | Buy → Buy | — | $2.36 | $2.40 | +1.7% | -1.7% | +0.0% | -0.4% | -4.7% | -2.5% |
| Aug 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.47 | $2.60 | +5.3% | -4.5% | -6.1% | -4.5% | -4.9% | -8.9% |
| May 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.59 | $2.89 | +11.6% | +3.9% | +2.7% | -1.9% | -2.7% | -6.2% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.98 | $3.00 | +0.7% | +1.0% | -7.0% | -13.1% | -9.7% | -10.7% |
| May 15 | Truist | Maintains | Buy → Buy | — | $2.96 | $3.00 | +1.4% | +0.7% | +1.7% | -6.4% | -12.5% | -9.1% |
| May 14 | Stifel | Maintains | Hold → Hold | — | $2.90 | $3.25 | +12.1% | +2.1% | +2.8% | +3.8% | -4.5% | -10.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.15 | -1.2% | +4.5% | +5.5% | +4.3% | +1.4% | +2.1% |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | $4.50 | $4.45 | -1.1% | +3.6% | -6.7% | -2.4% | -1.6% | -2.7% |
| Feb 27 | JP Morgan | Maintains | Overweight → Overweight | — | $4.63 | $4.75 | +2.6% | +11.0% | +10.6% | +6.0% | +6.7% | +17.9% |
| Jan 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.20 | $3.19 | -0.3% | -3.4% | -1.2% | +0.3% | -1.2% | +0.0% |
| Jan 5 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $3.39 | $2.80 | -17.4% | -13.9% | -7.7% | -10.0% | -6.5% | -5.3% |
| Jan 5 | Guggenheim | Downgrade | Buy → Neutral | — | $3.39 | $2.80 | -17.4% | -13.9% | -7.7% | -10.0% | -6.5% | -5.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.65 | $2.64 | -0.4% | +2.6% | +6.0% | +11.3% | +12.8% | +6.4% |
| Sep 25 | JP Morgan | Maintains | Overweight → Overweight | — | $3.65 | $3.63 | -0.5% | -3.8% | -7.9% | -7.1% | -6.6% | -13.2% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.59 | $4.61 | +0.4% | -7.4% | -2.8% | -5.4% | -8.3% | -8.5% |
| Aug 3 | EF Hutton | Maintains | Buy → Buy | — | $4.69 | $4.83 | +3.0% | +9.6% | -2.1% | -9.4% | -4.9% | -7.5% |
| Aug 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.69 | $4.83 | +3.0% | +9.6% | -2.1% | -9.4% | -4.9% | -7.5% |
| Jul 12 | Truist | Maintains | Buy → Buy | — | $5.79 | $5.89 | +1.7% | +0.2% | -9.8% | -14.3% | -8.6% | -8.1% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.85 | $4.79 | -1.2% | -0.8% | -2.9% | -3.1% | -2.1% | -2.5% |
| Jun 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.97 | $4.99 | +0.4% | -2.4% | -3.2% | -5.2% | -5.4% | -4.4% |
No insider trades available.
8-K
Unknown — 8-K Filing
Allogene Therapeutics completed a public offering, so the company raised capital for operations and clinical development, though dilution to existing shareholders occurred.
Apr 15
8-K
Unknown — 8-K Filing
This minimal 8-K disclosure provides no material information, suggesting either a routine administrative filing or potential missing substantive event details that investors need to understand Allogene's actual business developments and financial implications.
Apr 13
8-K
Unknown — 8-K Filing
Allogene's cema-cel shows compelling efficacy with 58.3% MRD negativity versus 16.7% in controls, suggesting strong clinical potential that could support regulatory approval and justify the therapy's commercial value.
Apr 13
8-K
Unknown — 8-K Filing
Allogene's imminent ALPHA3 interim data release could be a major catalyst—positive results would validate its allogeneic CAR-T platform and potentially drive significant stock appreciation for this clinical-stage biotech.
Mar 12
Data updated apr 24, 2026 5:21pm
· Source: massive.com